Semaglutide is a glucagon like peptide-1 used for the treatment of obesity.  It was first approved in the U.S in 2017 to improve glycemic control in patients with Type 2 diabetes. Recently, once weekly injection of Semaglutide has been shown to be an effective solution for patients who are having difficulty losing weight, losing as much as 15% of body fat in 6 months.  Semaglutide now carries an FDA approval indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in overweight or obese adult patients. 

Semaglutide is a drug that has recently gained attention for its potential to aid in weight loss. Originally developed as a treatment for type 2 diabetes, it belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is responsible for regulating blood sugar levels and appetite. 

Semaglutide enhances the activity of GLP-1 leading to a decrease in appetite and an increase in feelings of fullness, and lower blood sugar Clinical trials have shown promising results for semaglutide as a weight loss treatment. In a study of over 2,000 overweight or obese adults, those who took semaglutide for 68 weeks lost an average of 15% of their body weight, compared to 2.4% in the placebo group.

In addition, semaglutide has been shown to improve other health markers, such as blood pressure and cholesterol levels. This has led to the approval of semaglutide for the treatment of obesity in the United States. 

However, like all medications, semaglutide can cause side effects. The most common side effects include nausea, diarrhea, and vomiting. In rare cases, semaglutide can cause pancreatitis or thyroid cancer. It is also important to note that semaglutide should not be used as a standalone treatment for weight loss. It should be used in conjunction with a healthy diet and exercise regimen to achieve the best results. Cyanocobalamin may aid in the treatment of B12 deficiency. May help with increasing the metabolism of fats and carbohydrates.

Patients will be given lab slip at initial consultation for labs necessary to complete prior to beginning semaglutide. 

Patients may not be given semaglutide until the labs have been reviewed and approved.